11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
IMPORTANCE OF THE FIELD: The prevalence of obesity and type 2 diabetes is rising and reaching pandemic proportions. For this reason, identification of novel therapeutic targets is urgently needed. AREAS COVERED IN THIS REVIEW: The endoluminal enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2010
|
| _version_ | 1797068249287884800 |
|---|---|
| author | Morgan, SA Tomlinson, J |
| author_facet | Morgan, SA Tomlinson, J |
| author_sort | Morgan, SA |
| collection | OXFORD |
| description | IMPORTANCE OF THE FIELD: The prevalence of obesity and type 2 diabetes is rising and reaching pandemic proportions. For this reason, identification of novel therapeutic targets is urgently needed. AREAS COVERED IN THIS REVIEW: The endoluminal enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) catalyzes glucocorticoid activation in key metabolic tissues including skeletal muscle, liver and adipose tissue, and is strongly implicated in the pathogenesis of obesity, type 2 diabetes and the metabolic syndrome. Selective 11beta-HSD1 inhibitors limit local glucocorticoid availability and improve insulin sensitivity, glucose tolerance, lipid profiles and atherosclerosis. To date, there is a paucity of clinical studies using selective 11beta-HSD1 inhibitors; however, early indications show that these compounds have great therapeutic potential. WHAT THE READER WILL GAIN: We present a comprehensive overview of the background to the development of selective 11beta-HSD1 inhibitors, the preclinical data supporting 11beta-HSD1 as a therapeutic target, and the current status of clinical trials of these agents. TAKE HOME MESSAGE: Selective 11beta-HSD1 inhibitors have the potential to improve insulin sensitivity and may ultimately add to the treatment options available for patients with type 2 diabetes. However, further clinical studies are urgently required. |
| first_indexed | 2024-03-06T22:08:00Z |
| format | Journal article |
| id | oxford-uuid:50d20302-394a-4a27-ad08-fa7848b89089 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:08:00Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:50d20302-394a-4a27-ad08-fa7848b890892022-03-26T16:15:53Z11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:50d20302-394a-4a27-ad08-fa7848b89089EnglishSymplectic Elements at Oxford2010Morgan, SATomlinson, JIMPORTANCE OF THE FIELD: The prevalence of obesity and type 2 diabetes is rising and reaching pandemic proportions. For this reason, identification of novel therapeutic targets is urgently needed. AREAS COVERED IN THIS REVIEW: The endoluminal enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) catalyzes glucocorticoid activation in key metabolic tissues including skeletal muscle, liver and adipose tissue, and is strongly implicated in the pathogenesis of obesity, type 2 diabetes and the metabolic syndrome. Selective 11beta-HSD1 inhibitors limit local glucocorticoid availability and improve insulin sensitivity, glucose tolerance, lipid profiles and atherosclerosis. To date, there is a paucity of clinical studies using selective 11beta-HSD1 inhibitors; however, early indications show that these compounds have great therapeutic potential. WHAT THE READER WILL GAIN: We present a comprehensive overview of the background to the development of selective 11beta-HSD1 inhibitors, the preclinical data supporting 11beta-HSD1 as a therapeutic target, and the current status of clinical trials of these agents. TAKE HOME MESSAGE: Selective 11beta-HSD1 inhibitors have the potential to improve insulin sensitivity and may ultimately add to the treatment options available for patients with type 2 diabetes. However, further clinical studies are urgently required. |
| spellingShingle | Morgan, SA Tomlinson, J 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. |
| title | 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. |
| title_full | 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. |
| title_fullStr | 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. |
| title_full_unstemmed | 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. |
| title_short | 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. |
| title_sort | 11beta hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes |
| work_keys_str_mv | AT morgansa 11betahydroxysteroiddehydrogenasetype1inhibitorsforthetreatmentoftype2diabetes AT tomlinsonj 11betahydroxysteroiddehydrogenasetype1inhibitorsforthetreatmentoftype2diabetes |